Oncolytic adenoviruses coated with MHC-I tumor epitopes for a new oncolytic vaccine platform
- 289 Downloads
KeywordsMelanoma Human Melanoma Immunocompetent Mouse Oncolytic Adenovirus Personalized Cancer
Oncolytic adenoviruses (OAds) demonstrated great potential for the treatment of cancer in many pre-clinical studies. The pre-existing immunity and their immunodominance, however, still limit the success of oncolytic virotherapy in cancer patients. Thus, a transition from oncolytic agents to oncolytic vaccines seems to be necessary, since the involment of the immune system may play a key role in the efficacy of OAds.
Therefore, we developed a new oncolytic vaccine platform that uses the virus as adjuvant for MHC-I tumor epitopes that are loaded onto the viral capsid via electrostatic interactions. By using the model epitope SIINFEKL, we studied the efficacy of the peptide-coated conditionally replicating adenoviruses (PeptiCRAds) in immunocompetent mice bearing B16-OVA melanomas.
In conclusion, we demonstrated that the immunogenicity of OAds can be exploited to drive the immune response towards choosen epitopes and that this approach allows for rapid re-targeting without the need of genetic modifications, making PeptiCRAds a suitable platform for the next generation of highly personalized cancer vaccine immunotherapies.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.